A phase III randomised, double-blind trial to evaluate efficacy and safety of once daily empagliflozin 10 mg compared to placebo, in patients with chronic Heart Failure with reduced Ejection Fraction (HFrEF).

StatusActive
Effective start/end date25/04/1724/04/21

Funding

  • Boehringer Ingelheim International GmbH: $19,257.80

Keywords

  • Biotechnology & Drug Development, Cardiovascular Research